Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Iatric composite containing Rivastigmine and preparation method thereof

A technology of rivastigmine bitartrate and its composition, which is applied in the field of pharmaceutical compositions containing rivastigmine bitartrate and its preparation, can solve the problems of complex preparation process and low technical reproducibility, and achieve simple preparation process and Good reproducibility and low cost effect

Inactive Publication Date: 2008-06-25
BEIJING D VENTUREPHARM TECH DEV
View PDF3 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this technology needs to be coated twice, and the preparation process is complicated, resulting in low technical reproducibility

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Iatric composite containing Rivastigmine and preparation method thereof
  • Iatric composite containing Rivastigmine and preparation method thereof
  • Iatric composite containing Rivastigmine and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017]

[0018] Preparation method: pass rivastigmine bitartrate through a 100-mesh sieve, and pass other auxiliary materials through a 80-mesh sieve for later use; mix rivastigmine bitartrate, pregelatinized starch, and low-substituted hypromellose sodium in an equal-volume incremental method, and mix with water Prepare soft material, dry, measure moisture, granulate, add low-substituted hypromellose sodium and magnesium stearate, mix uniformly by equal addition method, and compress into tablets.

Embodiment 2

[0020]

[0021] Preparation method: pass rivastigmine bitartrate through a 100-mesh sieve, and pass other auxiliary materials through a 80-mesh sieve for later use; mix rivastigmine bitartrate, lactose, and microcrystalline cellulose in equal amounts, and use 10% starch slurry to make a soft material , dried, tested for moisture, granulated, added with magnesium stearate, mixed evenly, and compressed into tablets.

Embodiment 3

[0023]

[0024] Preparation method: pass rivastigmine bitartrate through a 100-mesh sieve, and pass other auxiliary materials through a 80-mesh sieve for later use; mix rivastigmine bitartrate, starch, and crospovidone in equal amounts, make soft materials with water, and dry. Measure the water content, granulate, add magnesium stearate, mix well, and compress into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a drug composition containing rivastigmine, which comprises the active ingredient and the excipient of the rivastigmine and exists in the form of a troche.The drug composition is mainly used for curing senile dementia caused by alzheimer disease and paralysis agitans.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating Alzheimer's disease and senile dementia caused by Parkinson's disease, in particular to a pharmaceutical composition containing rivastigmine bitartrate as an active ingredient. for tablets. Background technique [0002] Alzheimer's disease (Alzheimer's Disease, AD) is a primary gray matter encephalopathy, often occurs in the elderly. At present, cholinesterase inhibitors (ChEI) are an important class of drugs as alternative therapies in the treatment of AD, among which tacrine and donepezil have been put into clinical application, while rivastigmine bitartrate (rivastigmine, trade name Exelon) is It is the third cholinesterase inhibitor approved by FDA in April 2000. In July 2006, the U.S. FDA approved another indication of rivastigmine bitartrate for the treatment of mild to moderate dementia associated with Hutchinson's disease. This is the first FDA-approved treatment for Hutchinso...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/27A61K47/38A61K47/36A61K47/32A61K47/26A61P25/16A61P25/28
Inventor 孟凡静
Owner BEIJING D VENTUREPHARM TECH DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com